Tag:

Biogen Idec

Latest Headlines

Latest Headlines

PatientsLikeMe adds AstraZeneca to growing list of big-name clients

PatientsLikeMe has struck a 5-year deal to support R&D at AstraZeneca. The agreement tops off a busy and important 12 months for the patient network, in which it has also expanded relationships with Biogen, Roche's Genentech and Swiss biopharma Actelion.

PatientsLikeMe and Biogen reveal positive data from wearable device study for MS

PatientsLikeMe and Biogen revealed promising results from a new study that shows wearable devices can help monitor individuals with MS over time, providing additional information to clinicians and potentially increasing adherence among patients.

Big Pharma joins the U.K.'s genomics project with eyes on drug discovery

A group of the world's leading drugmakers have joined the U.K.'s ambitious initiative to sequence the genomes of 100,000 Britons, mining the data with hopes of finding new pathways to treat cancer and rare diseases.

Biogen's future: Bigger bets on CNS, smaller name

Biogen's latest evolution is more than just a nominal shift, according to its CEO, as the Big Biotech lops the Idec from its name and hopes to parlay its success in multiple sclerosis into some tough-to-treat diseases.

Biogen Alzheimer's drug reignites excitement

The success of Biogen Idec's closely watched antibody targeting beta amyloid proteins in Alzheimer's disease is again bringing some excitement to a category that has defeated earlier enthusiasm as drugs have failed in trials.

Biogen's Alzheimer's drug impresses in early study with Phase III on the way

Biogen Idec's heavily scrutinized Alzheimer's disease program came through with some positive early results, improving cognition and blasting away brain plaques in a small study many see as a validation of the company's ambitions in the field.

Analysts spread the love as Biogen Idec excites on MS, Alzheimer's

Biogen Idec has already primed expectations with remarks on promising results seen in early-stage results for its Alzheimer's drug BIIB037, so tomorrow's big reveal has focused a bright beam of attention on the company.

UPDATED: Biogen Idec's group-by-group cuts raise fears of more firings

Biogen Idec's decision to replace a group of 20 R&D staffers in chemistry and neurology wasn't the first internal staffing adjustment at the biotech trendsetter. Biogen Idec axed about 21 staffers last fall in a reorganization of clinical operations, R&D quality and compliance, according to sources close to the terminations. That move back in September/October was the first of two rounds of group firings in a quiet internal reorganization, raising concerns that more such department restructuring lies ahead.

Samsung Bioepis JV with Biogen Idec moves on Remicade biosimilar in Europe

South Korea's Samsung Bioepis has submitted a marketing authorization application to the European Medicines Agency for SB2, a biosimilar of autoimmune drug Remicade (infliximab) for moderate to severe rheumatoid arthritis.

Biogen Idec trims R&D staff, looks for new talent in chemistry, neurology

Biogen Idec took a look at its R&D group and decided to trim out a small group of its research staffers on Thursday. A spokesperson for the company said today that about 20 staffers were let go following a review of the company's long-term goals.